| ¿µ¹® | immunity | ÇÑ±Û | ¸é¿ª |
|---|---|---|---|
| ¼³¸í | ¸ö¼Ó¿¡ µé¾î¿Â º´¿ø ¹Ì»ý¹°¿¡ ´ëÇ×ÇÏ´Â Ç×ü¸¦ »ý»êÇÏ¿© µ¶¼Ò¸¦ ÁßÈÇϰųª º´¿ø ¹Ì»ý¹°À» Á׿©¼ ´ÙÀ½¿¡´Â ±× º´¿¡ °É¸®Áö ¾Êµµ·Ï µÈ »óÅÂ. ¶Ç´Â ±×·± ÀÛ¿ë. º´¿ø¼º¹Ì»ý¹° ¹× ÀÌÁ¾´Ü¹éÁú, ´Ù´çü-ÁöÁú µîÀÇ Ä§ÀÔ, ¶Ç´Â ÀÌÇü ¼öÇ÷, Á¶Á÷ ÀÌ½Ä µî, Æø³Ð°Ô ÀÚ±â ÀÌ¿ÜÀÇ À̹°ÀÌ Ä§ÀÔÇÏ¿´À» ¶§ Àڱ⸦ ¹æÀ§ÇÏ´Â »ýü¹ÝÀÀÀ» ¸»ÇÑ´Ù. ¿ø·¡ ÀÏ´Ü °¨¿°Áõ¿¡ °É¸®°í ȸº¹µÇ¸é, Æò»ý ±× º´¿¡ °É¸®Áö ¾Ê´Â ¡®Àç¹ßÇÏÁö ¾Ê´Â Çö»ó¡¯À» ÀǹÌÇÏ¿´Áö¸¸, ÇöÀç´Â »ç¶÷À̳ª µ¿¹°ÀÌ, À̹°ÀÇ Ä§ÀÔ¿¡ ´ëÇØ, °¢°¢ ´ëÀÀÇÑ Ç×ü¸¦ »ý»êÇÏ¿© ÀúÇ×¼ºÀ» ¾ò´Â »óŸ¦ ¸»ÇÑ´Ù. ¸é¿ª¿¡´Â ž¸é¼ºÎÅÍ °®°í ÀÖ´Â ÀÚ¿¬¸é¿ª°ú, »ýÈÄ Ç׿ø°ú Á¢ÇÏ°Ô µÊ¿¡ µû¶ó ¾ò¾îÁö´Â ȹµæ¸é¿ªÀÌ ÀÖÀ¸¸ç, ȹµæ¸é¿ª¿¡´Â ´Éµ¿¸é¿ª°ú ¼öµ¿¸é¿ªÀÌ ÀÖ´Ù. ´Éµ¿¸é¿ª¿¡´Â Áúº´ ȸº¹ ÈÄ¿¡ ¾ò¾îÁö´Â º´ÈÄ ¸é¿ª°ú ¹é½Åµî¿¡ ÀÇÇÑ ¿¹¹æÁ¢Á¾ °á°ú·Î ¾ò¾îÁö´Â ÀΰøÀû ¹æ¹ýÀÌ ÀÖ´Ù. ¼öµ¿¸é¿ªÀº ¸é¿ªÇ×ü¸¦ °®´Â Ç÷ûÀ» ÁÖ»çÇØ¼ ¾òÀ» ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | cell-mediated immunity | ÇÑ±Û | ¼¼Æ÷¸Å°³¸é¿ª |
|---|---|---|---|
| ¼³¸í | ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£ÇÏ´Â ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â ƯÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù. ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº ƯÁ¤ÇÑ ¹°Áú¿¡ °ü°èÇÏ´Â ¸é¿ªÀÌ ¾Æ´Ï¶ó ƯÁ¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö ÀÖ´Â ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀÎ °Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇÏ´Â ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀÇ È°µ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ ƯÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö ÀÖ´Â ¼¼Æ÷¸¦ »ý¼ºÇÏ°Ô ÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇÏ°Ô ÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. |
||
| CMI | 1) Cornell Medical Index 2) Cell-Mediated Immunity |
|---|---|
| CI | cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar... |
| CIDS | cellular immunity deficiency syndrome; circular intensity differential scattering; continuous insuli... |
| CMI | carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ... |
| HI | half-scan with interpolation; head injury; health insurance; hearing impaired; heart infusion; hemag... |
| CMI | Cell mediated immunity |
|---|---|
| MPS | Mononuclear-Phagocytic-System |
| PI | phagocytic index |
| phagocytic | <cell biology> Pertaining to or produced by phagocytes. Origin: L. Phagedaena, Gr Phago, To eat. (16 Dec 1997) |
|---|---|
| phagocytic dysfunction disorders immunodeficiency | Suppression in number or function of phagocytic cells such as in chronic granulomatous disease. Synonym: phagocytic dysfunction disorders immunodeficiency. Origin: L. Phagedaena, Gr Phago, To eat. (05 Mar 2000) |
| phagocytic dysfunction immunodeficiency | Suppression in number or function of phagocytic cells such as in chronic granulomatous disease. Synonym: phagocytic dysfunction disorders immunodeficiency. Origin: L. Phagedaena, Gr Phago, To eat. (05 Mar 2000) |
| phagocytic index | The average number of bacteria observed in the cytoplasm of polymorphonuclear leukocytes after mixing and incubating, at 37°C, 1) a suspension of washed, presumably normal leukocytes, 2) the serum to be tested for opsonin, and 3) a young culture of microorganisms that are causing disease in the patient. Origin: L. Phagedaena, Gr Phago, To eat. (05 Mar 2000) |
| phagocytic pneumonocyte | An alveolar phagocyte containing haemosiderin, carbon, or other foreign particles. Origin: L. Phagedaena, Gr Phago, To eat. (05 Mar 2000) |
| phagocytic vesicle | <cell biology> Membrane bounded vesicle enclosing a particle internalised by a phagocyte. The primary phagocytic vesicle phagosome) will subsequently fuse with lysosomes to form a secondary phagosome in which digestion will occur. Origin: L. Phagedaena, Gr Phago, To eat. (18 Nov 1997) |
| acquired immunity | <immunology> A form of cellular defense which identifies certain foreign substances (antigens) as harmful to the body. For this reason, the body can acquire resistance to a particular foreign agent. These foreign agents are then attacked by sensitised T lymphocytes (cellular immunity). White blood cells, plasma cells, B lymphocytes and other specialised immune system cells act in concert with T lymphocytes to produce antibodies (humoral immunity) that attach to the antigen directing T-cells to attack. Antibodies also stimulate the release of special chemical mediators in the blood (for example complement, interferon) that further enhance antigen destruction. (13 Nov 1997) |
| active immunity | <immunology> An organisms resistance to disease or infection, developed because the organisms immune system has produced antibodies after an infection or innoculation. (06 May 1997) |
| adoptive immunity | <immunology> Immunity to disease or infection conferred on a previously non-immune individual by transferring lymphocytes from a previously immune individual to the non-immune individual. (15 Jan 1998) |
| allograft immunity | <immunology> The recipient's immune system rejects tissue grafted from a genetically dissimilar donor (of the same species) and stages an immune attack against it. (09 Oct 1997) |
| antiviral immunity | Immunity resulting from virus infection, either naturally acquired or produced by intentional vaccination; compared to some bacterial immunity's, it is of relatively long duration, but this may be the result of infection-immunity rather than being peculiar to virus infection per se, since it occurs also in bacterial immunity after infections such as typhoid fever. (05 Mar 2000) |
| artificial active immunity | See: acquired immunity. (05 Mar 2000) |
| artificial passive immunity | See: acquired immunity. (05 Mar 2000) |
| bacteriophage immunity | The state induced in a bacterium by lysogenization, the lysogenic bacterium being insusceptible to further lysogenization or to a lytic cycle by a superinfecting bacteriophage, in contradistinction to bacteriophage resistance. (05 Mar 2000) |
| general immunity | Immunity associated with widely diffused mechanisms that tend to protect the body as a whole, as compared with local immunity. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|